Image Source: IPO Central
Infinium Pharmachem Ltd has commissioned a new manufacturing facility dedicated to contrast media raw materials, aiming to generate ₹1 billion in revenue from this segment. The Gujarat-based pharma company is expanding aggressively to meet rising demand in diagnostic imaging, strengthening its growth outlook and positioning in the healthcare supply chain.
Show more
Key Highlights:
-
Revenue Ambition: Infinium Pharmachem Ltd (INFM.NS) has set a bold target of ₹1 billion revenue from its contrast media segment, a fast-growing niche in diagnostic imaging.
-
New Facility Commissioned: The company has commissioned a new manufacturing plant in Gujarat, dedicated to producing contrast media raw materials, marking a significant capacity expansion.
-
Strategic Expansion: The facility spans 1,114 sq. meters at GIDC Sojitra, Anand district, and is expected to enhance supply reliability for hospitals and imaging centers.
-
Market Opportunity: With rising demand for diagnostic imaging in India and abroad, Infinium’s move strengthens its competitive edge in the pharma-chemical sector.
-
Investor Outlook: The expansion signals strong growth visibility, aligning with healthcare infrastructure investments and increasing adoption of advanced imaging technologies.
Contextual Note:
This development positions Infinium Pharmachem as a key player in the contrast media supply chain, supporting India’s healthcare modernization while opening new revenue streams in global markets.
Sources: Reuters, NSE India Press Release, Business Remediesbusinessremedies.com, MarketScreener
Stay Ahead – Explore Now!
Kalpataru Reports Strong Collections Growth Despite Pre-Sales Dip in Q3
Advertisement
Advertisement